BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32229687)

  • 1. Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor β (TGFβ).
    Cordeiro HG; de Sousa Faria AV; Ferreira-Halder CV
    Biol Chem; 2020 Aug; 401(9):1063-1069. PubMed ID: 32229687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
    Hoekstra E; Kodach LL; Das AM; Ruela-de-Sousa RR; Ferreira CV; Hardwick JC; van der Woude CJ; Peppelenbosch MP; Ten Hagen TL; Fuhler GM
    Oncotarget; 2015 Apr; 6(10):8300-12. PubMed ID: 25811796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase.
    Maccari R; Ottanà R; Ciurleo R; Paoli P; Manao G; Camici G; Laggner C; Langer T
    ChemMedChem; 2009 Jun; 4(6):957-62. PubMed ID: 19288492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
    Ruela-de-Sousa RR; Hoekstra E; Hoogland AM; Souza Queiroz KC; Peppelenbosch MP; Stubbs AP; Pelizzaro-Rocha K; van Leenders GJLH; Jenster G; Aoyama H; Ferreira CV; Fuhler GM
    Eur Urol; 2016 Apr; 69(4):710-719. PubMed ID: 26159288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
    Teng HW; Hung MH; Chen LJ; Chang MJ; Hsieh FS; Tsai MH; Huang JW; Lin CL; Tseng HW; Kuo ZK; Jiang JK; Yang SH; Shiau CW; Chen KF
    Sci Rep; 2016 Oct; 6():35308. PubMed ID: 27752061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
    Hoekstra E; Das AM; Swets M; Cao W; van der Woude CJ; Bruno MJ; Peppelenbosch MP; Kuppen PJ; Ten Hagen TL; Fuhler GM
    Oncotarget; 2016 Apr; 7(16):21922-38. PubMed ID: 26942883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of HT29 colorectal cancer cells to vemurafenib in three-dimensional collagen cultures.
    Kikuchi K; Hoshino D
    Cell Biol Int; 2020 Feb; 44(2):621-629. PubMed ID: 31736196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Violacein switches off low molecular weight tyrosine phosphatase and rewires mitochondria in colorectal cancer cells.
    Faria AVS; Fonseca EMB; Fernandes-Oliveira PS; de Lima TI; Clerici SP; Justo GZ; Silveira LR; Durán N; Ferreira-Halder CV
    Bioorg Chem; 2022 Oct; 127():106000. PubMed ID: 35853296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors.
    Ottanà R; Maccari R; Ciurleo R; Paoli P; Jacomelli M; Manao G; Camici G; Laggner C; Langer T
    Bioorg Med Chem; 2009 Mar; 17(5):1928-37. PubMed ID: 19217304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
    Sun T; Wang Q; Yu Z; Zhang Y; Guo Y; Chen K; Shen X; Jiang H
    Chembiochem; 2007 Jan; 8(2):187-93. PubMed ID: 17183521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
    Chen Q; Li Y; Li Z; Zhao Q; Fan L
    J Mol Histol; 2014 Apr; 45(2):153-9. PubMed ID: 23990346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of lncRNA EZR-AS1 inhibits proliferation, invasion, and migration of colorectal cancer cells through blocking transforming growth factor β signaling.
    Liu Z; Wang N; Wang F; Zhang S; Ding J
    Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31693738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight protein tyrosine phosphatase as signaling hub of cancer hallmarks.
    Faria AVS; Fonseca EMB; Cordeiro HG; Clerici SP; Ferreira-Halder CV
    Cell Mol Life Sci; 2021 Feb; 78(4):1263-1273. PubMed ID: 33052434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells.
    Choudhry MA; Sir O; Sayeed MM
    Shock; 2001 Mar; 15(3):193-9. PubMed ID: 11236902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
    Faria AVS; Clerici SP; de Souza Oliveira PF; Queiroz KCS; Peppelenbosch MP; Ferreira-Halder CV
    Mol Cell Biochem; 2020 Mar; 466(1-2):83-89. PubMed ID: 32016696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEGF6 Promotes the Epithelial-to-Mesenchymal Transition via the TGFβ/SMAD Signaling Pathway in Colorectal Cancer Metastasis.
    Hu H; Wang M; Wang H; Liu Z; Guan X; Yang R; Huang R; Tang Q; Zou C; Wang G; Gao X; Wang X
    Cell Physiol Biochem; 2018; 46(5):1895-1906. PubMed ID: 29719292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation.
    Zambuzzi WF; Granjeiro JM; Parikh K; Yuvaraj S; Peppelenbosch MP; Ferreira CV
    Cell Physiol Biochem; 2008; 22(5-6):497-506. PubMed ID: 19088431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.